Shop Detailed

Descriptions

Description

Cagrilintide is a long-acting amylin analogue designed to mimic key actions of the naturally occurring hormone amylin. Amylin is involved in appetite regulation, satiety, gastric emptying, and glucose-related signaling. Cagrilintide is being investigated as a standalone therapy and in combination with semaglutide (CagriSema) for weight-management research. Clinical research has demonstrated meaningful reductions in body weight with cagrilintide, while gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation have been among the reported adverse events. Cagrilintide remains an investigational compound, with ongoing Phase 3 development.

Best Use — Research

For a research-use-only catalog, cagrilintide is appropriate for research involving:

• Amylin receptor biology
• Appetite and satiety signaling
• Energy-intake regulation
• Gastric-emptying mechanisms
• Glucose and metabolic regulation
• Adiposity and body-weight regulation
• Obesity and metabolic-disease research
• Investigation of amylin-based therapies, including combination approaches with GLP-1 agonists

Purity: ≥99%

Verified: Third-party tested